老年非瓣膜性房颤患者华法林抗凝强度的研究进展
CSTR:
作者:
作者单位:

(1. 扬州大学医学院临床医学系,扬州 225001;2. 苏北人民医院心血管内科,扬州 225001)

作者简介:

通讯作者:

中图分类号:

R541.7;R592

基金项目:

江苏省科技厅临床医学科技专项(BL2013022)


Research progress on anticoagulant effect of warfarin in the elderly patients with non-valvular atrial fibrillation
Author:
Affiliation:

(1. Department of Clinical Medicine, Medical College of Yangzhou University, Yangzhou 225001, China;2. Department of Cardiology, Northern Jiangsu People′s Hospital, Yangzhou 225001, China)

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    流行病学调查显示房颤的发病率逐年上升,尤其在老年人中,年龄越大,其发病率和死亡率越高。多个临床试验显示,目前华法林仍是治疗房颤的主要药物。欧美国家的房颤指南建议将国际标准化比值(INR)控制在2.0~3.0,但亚洲和欧美人群之间存在种族差异,应适当降低华法林抗凝强度,尤其是对于有高卒中、高出血风险的老年非瓣膜性房颤(NVAF)患者,INR控制在1.5~2.5是安全有效的,但这一结论仍缺乏大量的临床试验及循证医学依据。

    Abstract:

    Epidemiological surveys show that the incidence of atrial fibrillation has been increasing year by year, especially in the elderly, and the morbidity and mortality increase with age. Several clinical trials report that warfarin remains the main drug for the treatment of atrial fibrillation. The international normalized ratio (INR) is recommended as between 2.0 and 3.0 in European and American guidelines; however, there are racial differences between Asian and European and American populations. Warfarin anti-coagulation should be appropriately reduced, especially in the elderly patients with non-valvular atrial fibrillation who have high risks of stroke and bleeding. INR of 1.5-2.5 is safe and effective for them, which warrants a large number of clinical trials and evidence basis.

    参考文献
    相似文献
    引证文献
引用本文

顾敏,顾翔.老年非瓣膜性房颤患者华法林抗凝强度的研究进展[J].中华老年多器官疾病杂志,2019,18(3):232-236
DOI:10.11915/j. issn.1671-5403.2019.03.047

复制
分享
相关视频

文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2018-09-15
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2019-03-27
  • 出版日期:
文章二维码